Meeting
2023 ASCO Annual Meeting
Clinical and genomic characterization of early-onset pancreatic cancer.
Authors
Florian Castet
Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
Florian Castet , Carles Fabregat Franco , Gloria Castillo , Victor Navarro , Eduardo García-Galea , Alexandre Sierra , Ana Carmona-Alonso , Tian Tian , Ana Vivancos , Teresa Macarulla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4018)
DOI
10.1200/JCO.2023.41.16_suppl.4018
Abstract #
4018
Poster Bd #
339
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DIsCOvER: A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreas cancer during first-line chemotherapy.
First Author: Felix Keil
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
First Author: Junwei Wu
Poster
2023 ASCO Annual Meeting
Alteration of gut microbiota composition in patients with cholangiocarcinoma with non-responsiveness to first-line chemotherapy: A pilot study.
First Author: Thanika Ketpueak
Poster
2023 ASCO Annual Meeting
Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.
First Author: Pooja Mittal